Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $26.38, up 1.15% with elevated volume. Technical indicators are bearish overall, with moving averages and oscillators signaling caution. The stock lacks traditional fundamental metrics like P/E or revenue, as it is an ETF, and its value is tied to interest rate expectations. Recent news highlights strong trading volume, suggesting heightened investor attention amid bond market volatility.

The outlook for TMF hinges on interest rate trends, with potential upside if rates fall but significant downside risk if they rise. Investors face volatility from macroeconomic shifts and the ETF's leveraged structure, which amplifies gains and losses. Key risks include Federal Reserve policy changes and inflation dynamics, making it suitable only for those comfortable with high risk and short-term trading.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.